

SUPPLEMENTAL TABLES

Characteristics	Chemotherapy (n=1500)	Immunotherapy (n=132)	p-value
Pathologic T stage, no. (%)			
T0/Tis	187 (12.5%)	9 (6.8%)	
T1a	39 (2.6%)	5 (3.8%)	
T1b	156 (10.4%)	7 (5.3%)	
T1c	187 (12.5%)	19 (14.4%)	0.18
T2a	272 (18.1%)	26 (19.7%)	
T2b	185 (12.3%)	20 (15.2%)	
T3	298 (19.9%)	32 (24.2%)	
T4	172 (11.5%)	12 (9.1%)	
Unknown	4 (0.3%)	2 (1.5%)	
Pathologic N stage, no. (%)			
N0	686 (54.2%)	46 (54.8%)	
N1	221 (17.5%)	19 (22.6%)	0.54
N2	356 (28.1%)	19 (22.6%)	
N3	2 (0.2%)	0 (0.0%)	
Unknown	235	48	
Pathologic M stage, no. (%)			
M0	483 (97.6%)	68 (98.9%)	0.61
M1	12 (2.4%)	1 (1.5%)	
Unknown	1005	63	
Nodal upstaging, no. (%)	95 (6.5%)	12 (9.3%)	0.22
Nodal downstaging, no. (%)	569 (49.8%)	25 (30.1%)	0.001
Lymph nodes examined, no. (%)	1469 (98.1%)	129 (97.7%)	0.79
Number of lymph nodes examined (median, IQR)	14.0 (8.0, 24.0)	17.0 (11.0, 28.5)	0.005
Surgical margin, no. (%)			0.78
Negative	1409 (94.8%)	124 (95.4%)	
Positive	77 (5.2%)	6 (4.6%)	
Unknown	14	2	
Length of stay, (median IQR)	4.0 (3.0, 6.0)	4.0 (3.0, 6.0)	0.042
30-day readmission, no. (%)			
No	1441 (96.6%)	124 (94.7%)	0.26
Yes	51 (3.4%)	7 (5.3%)	
Unknown	8	1	
30-day mortality, no. (%)			
No	1255 (98.8%)	68 (97.1%)	0.22
Yes	15 (1.2%)	2 (2.9%)	
Unknown	230	62	
90-day mortality, no. (%)			
No	1219 (96.3%)	68 (97.1%)	0.71
Yes	47 (3.7%)	2 (2.9%)	
Unknown	234	62	
Resection approach, no. (%)			
VATS	1036 (69.1%)	72 (54.5%)	<0.001
Robot	464 (30.9%)	60 (45.5%)	
Conversion, no. (%)	220 (14.7%)	18 (13.6%)	0.75

Supplemental Table I. Pathological characteristics and perioperative outcomes of the subcohort of patients with clinical stage I-III NSCLC undergoing minimally invasive lobectomy after neoadjuvant chemotherapy vs neoadjuvant immunotherapy.

Characteristics	Open Lobectomy (n=86)	MIS Lobectomy (n=132)	p-value
Pathologic T stage, no. (%)			
T0/Tis	6 (7.0%)	9 (6.8%)	0.21
T1a	3 (3.5%)	5 (3.8%)	
T1b	9 (10.5%)	7 (5.3%)	
T1c	10 (11.6%)	19 (14.4%)	
T2a	13 (15.1%)	26 (19.7%)	
T2b	13 (15.1%)	20 (15.2%)	
T3	14 (16.3%)	32 (24.2%)	
T4	18 (20.9%)	12 (9.1%)	
Unknown	0 (0.0%)	2 (1.5%)	
Pathologic N stage, no. (%)			
N0	31 (70.5%)	46 (54.8%)	0.22
N1	6 (13.6%)	19 (22.6%)	
N2	7 (15.9%)	19 (22.6%)	
Unknown	42	48	
Pathologic M stage, no. (%)			
M0	33 (100.0%)	68 (98.6%)	0.49
M1	0 (0.0%)	1 (1.5%)	
Unknown	53	63	
Nodal upstaging, no. (%)	4 (4.8%)	12 (9.3%)	0.29
Nodal downstaging, no. (%)	21 (43.8%)	25 (30.1%)	0.12
Lymph nodes examined, no. (%)	82 (95.3%)	129 (97.7%)	0.33
Number of lymph nodes examined (median, IQR)	17.0 (11.0, 26.0)	17.0 (11.0, 28.5)	0.76
Surgical margin, no. (%)			
Positive	79 (92.9%)	124 (95.4%)	0.45
Negative	6 (7.1%)	6 (4.6%)	
Unknown	1	2	
Length of stay (median IQR)	4.0 (3.0, 7.0)	4.0 (3.0, 6.0)	0.11
Readmission (30 day), no. (%)			
No	80 (93.0%)	124 (94.7%)	0.62
Yes	6 (7.0%)	7 (5.3%)	
Unknown	0	1	
30-day mortality, no. (%)			
No	40 (100.0%)	68 (97.1%)	0.28
Yes	0 (0.0%)	2 (2.9%)	
Unknown	46	62	
90-day mortality, no. (%)			
No	39 (97.5%)	68 (97.1%)	0.91
Yes	1 (2.5%)	2 (2.9%)	
Unknown	46	62	

578

579

580

581

582

583

584

Supplemental Table II. Pathological characteristics and perioperative outcomes of the subcohort of patients with clinical stage I-III NSCLC undergoing minimally invasive vs open lobectomy after neoadjuvant immunotherapy.